{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:05:52Z","timestamp":1780376752861,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant support to Prof. Rossi: FORICA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>Familial hyperaldosteronism type 1 (FH-1) is a rare autosomal dominant form of primary aldosteronism, which features a marked phenotypic heterogeneity, ranging from mild to severe forms of arterial hypertension that can be complicated by stroke and cardiovascular events at a young age. As affected patients usually reach the fertile age, transmission of the disease to offspring is common. Notwithstanding this, reports of FH-1 in pregnancy are limited and there is a lack of treatment guidelines.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and results<\/jats:title><jats:p>We searched the PubMed and EuropePMC databases with a PICO strategy to retrieve available information on management of FH-1 patients during pregnancy. We could identify seven relevant articles, which are herein reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Based on available information on pathophysiology and treatment of FH-1 in pregnancy, recommendations for the rational management of FH-1 in pregnancy are provided.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s12020-021-02763-5","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T06:02:37Z","timestamp":1622095357000},"page":"5-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A systematic review of pathophysiology and management of familial hyperaldosteronism type 1 in pregnancy"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-1636","authenticated-orcid":false,"given":"Viola","family":"Sanga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3639-4086","authenticated-orcid":false,"given":"Teresa Maria","family":"Seccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-0931","authenticated-orcid":false,"given":"Gian Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"issue":"1","key":"2763_CR1","first-page":"1","volume":"101","author":"IS Salti","year":"1969","unstructured":"I.S. Salti, M. Stiefel, J.L. Ruse, J.C. Laidlaw, Non-tumorous \u2018primary\u2019 aldosteronism. I. Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism). Can. Med. Assoc. J. 101(1), 1\u201310 (1969)","journal-title":"Can. Med. Assoc. J."},{"issue":"22","key":"2763_CR2","first-page":"1109","volume":"95","author":"DJ Sutherland","year":"1966","unstructured":"D.J. Sutherland, J.L. Ruse, J.C. Laidlaw, Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can. Med. Assoc. J. 95(22), 1109\u201319 (1966)","journal-title":"Can. Med. Assoc. J."},{"issue":"5","key":"2763_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1440-1681.1992.tb00462.x","volume":"19","author":"M Stowasser","year":"1992","unstructured":"M. Stowasser, R.D. Gordon, T.J. Tunny, S.A. Klemm, W.L. Finn, A.L. Krek, Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism. Clin. Exp. Pharmacol. Physiol. 19(5), 319\u201322 (1992)","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"issue":"6018","key":"2763_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.1198785","volume":"331","author":"M Choi","year":"2011","unstructured":"M. Choi, U.I. Scholl, P. Yue, et al., K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 331(6018), 768\u201372 (2011).","journal-title":"Science"},{"issue":"7","key":"2763_CR5","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1073\/pnas.1121407109","volume":"109","author":"UI Scholl","year":"2012","unstructured":"U.I. Scholl, C. Nelson-Williams, P. Yue et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc. Natl Acad. Sci. USA 109(7), 2533\u20138 (2012)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2763_CR6","doi-asserted-by":"publisher","first-page":"e06315","DOI":"10.7554\/eLife.06315","volume":"4","author":"UI Scholl","year":"2015","unstructured":"U.I. Scholl, G. St\u00f6lting, C. Nelson-Williams et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife 4, e06315 (2015)","journal-title":"Elife"},{"issue":"6","key":"2763_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1161\/HYPERTENSIONAHA.118.11150","volume":"71","author":"L Lenzini","year":"2018","unstructured":"L. Lenzini, S. Prisco, B. Caroccia, G.P. Rossi, Saga of familial hyperaldosteronism yet a new channel. Hypertension 71(6), 1010\u20131014 (2018)","journal-title":"Hypertension"},{"issue":"5","key":"2763_CR8","first-page":"682","volume":"48","author":"GT McMahon","year":"2004","unstructured":"G.T. McMahon, R.G. Dluhy, Glucocorticoid-remediable aldosteronism. Cardiol. Rev. 48(5), 682\u20136 (2004)","journal-title":"Cardiol. Rev."},{"issue":"1 Pt 2","key":"2763_CR9","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1161\/01.HYP.31.1.445","volume":"31","author":"WR Litchfield","year":"1998","unstructured":"W.R. Litchfield, B.F. Anderson, R.J. Weiss, R.P.D.R. Lifton, Intracranial aneurysm and hemorrhagic stroke in glucocorticoid- remediable aldosteronism. Hypertension 31(1 Pt 2), 445\u201350 (1998)","journal-title":"Hypertension"},{"issue":"6357","key":"2763_CR10","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/355262a0","volume":"355","author":"RP Lifton","year":"1992","unstructured":"R.P. Lifton, R.G. Dluhy, M. Powers et al. A chimaeric ll\u03b2-hydroxylase\/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355(6357), 262\u20135 (1992)","journal-title":"Nature"},{"issue":"12","key":"2763_CR11","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.1210\/jcem.83.12.5309","volume":"83","author":"AA MacConnachie","year":"1998","unstructured":"A.A. MacConnachie, K.F. Kelly, A. McNamara et al. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid remediable aldosteronism. J. Clin. Endocrinol. Metab. 83(12), 4328\u201331 (1998)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2763_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.coph.2014.12.005","volume":"21","author":"L Lenzini","year":"2015","unstructured":"L. Lenzini, G.P. Rossi, The molecular basis of primary aldosteronism: from chimeric gene to channelopathy. Curr. Opin. Pharmacol. 21, 35\u201342 (2015)","journal-title":"Curr. Opin. Pharmacol."},{"key":"2763_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000360870","volume":"43","author":"JW Funder","year":"2014","unstructured":"J.W. Funder,, Genetics of primary aldosteronism. Cardiovasc. Issues Endocrinol. 43, 70\u20138 (2014).","journal-title":"Cardiovasc. Issues Endocrinol."},{"issue":"11","key":"2763_CR14","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"G.P. Rossi, G. Bernini, C. Caliumi et al. A prospective study of the prevalence of primary aldosteronism in 1,125 Hypertensive Patients. J. Am. Coll. Cardiol. 48(11), 2293\u2013300 (2006)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"14","key":"2763_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"S. Monticone, J. Burrello, D. Tizzani et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J. Am. Coll. Cardiol. 69(14), 1811\u20131820 (2017)","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"2763_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/jhh.2014.49","volume":"29","author":"C Campino","year":"2015","unstructured":"C. Campino, P. Trejo, C.A. Carvajal et al. Pregnancy normalized familial hyperaldosteronism type I: A novel role for progesterone. J. Hum. Hypertens. 29(2), 138\u20139 (2015)","journal-title":"J. Hum. Hypertens."},{"issue":"2","key":"2763_CR17","first-page":"135","volume":"39","author":"E Hamilton","year":"2009","unstructured":"E. Hamilton, C. O\u2019Callaghan, R.M. O\u2019Brien et al. Familial hyperaldosteronism type 1 in pregnancy. Intern. Med. J. 39(2), 135\u20136 (2009)","journal-title":"Med. J."},{"issue":"2","key":"2763_CR18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1161\/01.HYP.35.2.668","volume":"35","author":"JA Wyckoff","year":"2000","unstructured":"J.A. Wyckoff, E.W. Seely, S. Hurwitz, B.F. Anderson, R.P. Lifton, R.G. Dluhy, Glucocorticoid-remediable aldosteronism and pregnancy. Hypertension 35(2), 668\u201372 (2000)","journal-title":"Hypertension"},{"issue":"7","key":"2763_CR19","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1210\/jcem.87.7.8647","volume":"87","author":"P Mulatero","year":"2002","unstructured":"P. Mulatero, S.M.Di Cella, T.A. Williams et al. Glucocorticoid remediable aldosteronism: Low morbidity and mortality in a four-generation Italian pedigree. J. Clin. Endocrinol. Metab. 87(7), 3187\u201391 (2002)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"2763_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/08037051.2020.1863771","volume":"30","author":"V Sanga","year":"2021","unstructured":"V. Sanga, L. Lenzini, T.M. Seccia, G.P. Rossi, Familial hyperaldosteronism type 1 and pregnancy: successful treatment with low dose dexamethasone. Blood Press 30(2), 133\u2013137 (2021)","journal-title":"Blood Press"},{"issue":"5","key":"2763_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/HJH.0000000000000892","volume":"34","author":"GP Rossi","year":"2016","unstructured":"G.P. Rossi, V. Bisogni, A useful tool to improve the case detection rate of primary aldosteronism: The aldosterone -renin ratio (ARR)-App. J. Hypertens. 34(5), 1019\u201321 (2016)","journal-title":"J. Hypertens."},{"issue":"3","key":"2763_CR22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/0895-7061(94)00213-U","volume":"8","author":"MA Brown","year":"1995","unstructured":"M.A. Brown, S.T.P. Thou, J.A. Whitworth, Stimulation of aldosterone by ACTH in normal and hypertensive pregnancy. Am. J. Hypertens. 8(3), 260\u20137 (1995)","journal-title":"Am. J. Hypertens."},{"issue":"2","key":"2763_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1177\/1753944708100180","volume":"3","author":"G Escher","year":"2009","unstructured":"G. Escher, Hyperaldosteronism in pregnancy. Ther. Adv. Cardiovasc. Dis. 3(2), 123\u201332 (2009)","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"5","key":"2763_CR24","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1210\/jcem-63-5-1199","volume":"63","author":"RS Goland","year":"1986","unstructured":"R.S. Goland, S.L. Wardlaw, R.I. Stark, L.S. Brown, A.G. Frantz, High levels of corticotropin-releasing hormone immunoactivity in maternal and fetal plasma during pregnancy. J. Clin. Endocrinol. Metab. 63(5), 1199\u2013203 (1986)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2763_CR25","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1081\/ERC-120016824","volume":"28","author":"M Quinkler","year":"2002","unstructured":"M. Quinkler, S. Diederich, Difference of in vivo and in vitro antimineralocorticoid potency of progesterone. Endocr. Res. 28(4), 465\u201370 (2002)","journal-title":"Endocr. Res."},{"key":"2763_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-11-76","volume":"11","author":"A Vecchiola","year":"2013","unstructured":"A. Vecchiola, C.F. Lagos, C.A. Fuentes et al. Different effects of progesterone and estradiol on chimeric and wild type aldosterone synthase in vitro. Reprod. Biol. Endocrinol. 11, 76 (2013)","journal-title":"Reprod. Biol. Endocrinol."},{"key":"2763_CR27","unstructured":"N.C. Nicolaides, A.N. Pavlaki, A.M. Maria Alexandra, et al. \u2018Glucocorticoid Therapy and Adrenal Suppression - Endotext - NCBI Bookshelf\u2019 (2018).."},{"issue":"6","key":"2763_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40292-020-00415-9","volume":"27","author":"GP Rossi","year":"2020","unstructured":"G.P. Rossi, V. Bisogni, G. Rossitto et al. Practice recommendations for diagnosis and treatment of the most common forms of secondary hypertension. High Blood Press. Cardiovasc. Prev. 27(6), 547\u2013560 (2020)","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"2763_CR29","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.ijchy.2020.100029","volume":"5","author":"GP Rossi","year":"2020","unstructured":"G.P. Rossi, V. Bisogni, A.V. Bacca et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int. J. Cardiol. Hypertens. 5, 100029 (2020)","journal-title":"Int. J. Cardiol. Hypertens."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02763-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T18:46:21Z","timestamp":1672253181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02763-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["2763"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02763-5","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"18 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}